Cancer Pain - Pipeline Review, H2 2020

November 2020 | 154 pages | ID: C2B24D162B9EN
Global Markets Direct

Abstracts

Cancer Pain - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 7, 7, 1, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cancer Pain- Overview
Cancer Pain- Therapeutics Development
Cancer Pain- Therapeutics Assessment
Cancer Pain- Companies Involved in Therapeutics Development
Cancer Pain- Drug Profiles
Cancer Pain- Dormant Projects
Cancer Pain- Discontinued Products
Cancer Pain- Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cancer Pain, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2020
Cancer Pain - Pipeline by AngioChem Inc, H2 2020
Cancer Pain - Pipeline by Aphios Corp, H2 2020
Cancer Pain - Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
Cancer Pain - Pipeline by AstraZeneca Plc, H2 2020
Cancer Pain - Pipeline by Beckley Canopy Therapeutics Ltd, H2 2020
Cancer Pain - Pipeline by Cassava Sciences Inc, H2 2020
Cancer Pain - Pipeline by Concentric Analgesics Inc, H2 2020
Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2020
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2020
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2020
Cancer Pain - Pipeline by Intec Pharma Ltd, H2 2020
Cancer Pain - Pipeline by IntelGenx Corp, H2 2020
Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2020
Cancer Pain - Pipeline by Jiangsu Huatai Chenguang Pharmaceutical Co Ltd, H2 2020
Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2020
Cancer Pain - Dormant Projects, H2 2020
Cancer Pain - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cancer Pain, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020